Mexico
Tuberculosis profile
Population  2013 122 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.2 (2.2–2.2) 1.8 (1.8–1.8)
Mortality (HIV+TB only) 0.36 (0.28–0.46) 0.3 (0.23–0.37)
Prevalence  (includes HIV+TB) 31 (14–55) 26 (11–45)
Incidence  (includes HIV+TB) 25 (23–28) 21 (18–23)
Incidence (HIV+TB only) 2.3 (2.2–2.3) 1.8 (1.8–1.9)
Case detection, all forms (%) 82 (73–92)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.4 (2.1–2.8) 6.5 (5.1–7.8)
MDR-TB cases among notified pulmonary
TB cases
390 (340–450) 99 (78–120)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 13 239   770
Pulmonary, clinically diagnosed 2 841   161
Extrapulmonary 3 623   74
       
Total new and relapse 20 708    
Previously treated, excluding relapses 598    
Total cases notified 21 306    
Among 20 708 new and relapse cases:
805 (4%) cases aged under 15 years; male:female ratio: 1.6
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 33 (<1%) 188 (12%) 224
Laboratory-confirmed RR-/MDR-TB cases     163
Patients started on MDR-TB treatment     162
TB/HIV 2013 Number (%)
TB patients with known HIV status 15 749 (74)
HIV-positive TB patients 1 192 (8)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 836 (70)
HIV-positive TB patients on antiretroviral therapy (ART) 512 (43)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 80
Previously treated cases, excluding relapse, registered in 2012 52
HIV-positive TB cases, all types, registered in 2012 57
RR-/MDR-TB cases started on second-line treatment in 2011 69
XDR-TB cases started on second-line treatment in 2011 100
Laboratories 2013  
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 2.7
Drug susceptibility testing (per 5 million population) 0.7
Sites performing Xpert MTB/RIF 11
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 24
% Funded domestically 100%
% Funded internationally 0%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-05-27 Data: www.who.int/tb/data